BAYRY
Roundup: the never-ending sequel
Bayer’s Bill Anderson basically told Axios what investors have been hoping to hear for years: please, can we close the book on Roundup already? The company says the herbicide is a core ag product, but the legal cloud around it has been a giant headache since Bayer inherited the mess with its 2018 Monsanto deal.
Why this matters
The stakes are not exactly small. Bayer recently disclosed a $7.25 billion settlement tied to the Roundup litigation, and the Supreme Court is still weighing a decision that could shape the product’s future in the U.S. That means this isn’t just about lawyers doing lawyer stuff — it’s about whether Bayer can keep selling a flagship product without a fresh thunderstorm of lawsuits overhead.
A company trying to move on
Anderson called the settlement and the legal battle "significant milestones" for Bayer’s recovery, which is corporate-speak for: we’d really like to stop talking about this. He also said Bayer wants a "predictable regulatory regime," a phrase that sounds boring until you remember how much money unpredictable rules can vaporize.
The bigger picture
There’s also a little political drama in the background, with reported resistance from HHS Secretary Robert F. Kennedy Jr. even as the EPA backs the product. Meanwhile, Bayer is pushing ahead with new products like the insecticide Plenexos, which is already in Latin America but not yet in the U.S. Big picture: Bayer isn’t just fighting for Roundup — it’s fighting for the right to look like a normal company again.